NCT05904093View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

May 14, 2026

Study Completion Date

May 14, 2026

Conditions
Sickle Cell DiseaseHb-SS DiseaseHemoglobin SDisease Sickle Cell AnemiaSickle Cell DisordersHemoglobin Beta Thalassemia Disease
Interventions
DRUG

Fostamatinib

Fostamatinib will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, orally, twice a day for 28 days (total 42 days).

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH